• 1
    World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:3547.
  • 2
    Mizukoshi E, Rehermann B. Immune responses and immunity in hepatitis C virus infection. J Gastroenterol 2001; 36:799808.
  • 3
    Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81:16311648.
  • 4
    Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296305 Available at:
  • 5
    Pawlotsky JM. Hepatitis C virus infection: Virus/host interactions. J Viral Hepat 1998; 5:38.
  • 6
    Marrone A, Sallie R. Genetic heterogeneity of hepatitis C virus: The clinical significance of genotypes and quasispecies behavior. Clin Lab Med 1996; 16:429449.
  • 7
    Rosen HR, Schwartz JM. Hepatitis C quasispecies and severity of recurrence: Cause, consequence, or coincidence? Liver Transpl 2002; 8:646648.
  • 8
    Polyak SJ. Hepatitis C virus-cell interactions and their role in pathogenesis. Clin Liver Dis 2003; 7:6788.
  • 9
    Yao ZQ, Nguyen DT, Hiotellis AI, Hahn YS. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J Immunol 2001; 167:52645272.
  • 10
    Valiante N. Natural killer cells and other variations on the theme of a cytotoxic lymphocyte. Hepatic Inflammation and Immunity Meeting, Galveston, TX, March 24, 2002.
  • 11
    Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence and disease. Proc Natl Acad Sci USA 99: 1566115668.
  • 12
    Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195:3551.
  • 13
    Tseng C-TK, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195:4349.
  • 14
    Wack A, Soldaini E, Tseng C-T, Nuti S, Klimpel GR, Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immol 2001; 31:166175.
  • 15
    Deignan T, Curry MP, Doherty DG, Golden-Mason L, Volkov Y, Norris S, et al. Decrease in hepatic CD56+ T cells and Vα24+ natural killer T cells in chronic hepatitis C viral infection. J Hepatol 2002; 37:101108.
  • 16
    Kawarabayashi N, Seki S, Hatsuse K, Ohkawa T, Koike Y, Aihara T, et al. Decrease of CD56+ T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000; 32:962969.
  • 17
    Leistikow R, Boslaugh T, Ham J, Nelson D, Wertheimer A, Rosen HR. Direct ex vivo functional analysis of intrahepatic T, NKT and NK cells from HCV-infected and non-infected explants. Poster, AASLD, Boston, 2002 [abstract 421]. Hepatology 2002; 36:178.
  • 18
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998: 392: 245252.
  • 19
    Liu Y-J, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity, and cross-regulation. Nat Immunol 2001; 2:585589.
  • 20
    Reis E, Sousa C, Sher A, Kaye P. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 1999; 11:392399.
  • 21
    Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. Novel CD4+ and CD8+ T cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37:577589.
  • 22
    Wertheimer AM, Rosen HR. Direct ex-vivo enumeration of human dendritic cell (DC) populations demonstrates HCV infection is associated with loss in both myeloid (MDC) and plasmacytoid (PDC) types. Poster, AASLD, Boston, 2002 [abstract 48]. Hepatology 2002; 36:268.
  • 23
    Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus infected individuals. J Immunol 1999; 162:55845591.
  • 24
    Bain C, Fatmi A, Zoulim F, Zarski J, Trpo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastoenterology 2001; 120:512524.
  • 25
    Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97:31713176.
  • 26
    Sarobe P, Lasarte JJ, Casares N, Lopez-Diaz de Cerio A, Baixeras E, Labarga P, et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76: 50625070
  • 27
    Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, et al. Clinical outcome of hypogammaglobulinemic patients following outbreak of acute hepatitis C: 2 Year follow-up. Clin Exp Immunol 1997; 110:48.
  • 28
    Zibert A, Kraas W, Meisel H, Jung G, Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 1997; 71:41234127.
  • 29
    Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339344.
  • 30
    Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 1999; 73:11181126.
  • 31
    Mehta SH, Cox A, Hoover DR, Wang X-H, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:14781483.
  • 32
    Takaki A, Wiese M, Maerten G, Depla E, Siefert U, Liebtrau A, et al. Cellular immune responses persist, humoral response responses decrease two decades after recovery from a single source outbreak of hepatitis C. Nat Med 2000; 6:578582.
  • 33
    Moser M, Murphy KM. Dendritic cell regulation of Th1-Th2 development. Nat Immunol 2001; 1:199203.
  • 34
    Nelson DR, Lauwers GY, Lau JYN, Davis GL. Interleukin-10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial in interferon nonresponders. Gastroenterology 2000; 118:655660.
  • 35
    Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706714.
  • 36
    Gerlach JT, Diepolder HM, Jung M-C, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933941.
  • 37
    Rosen HR, Miner C, Lewinsohn D, Sasaki AW, Conrad AJ, Bakke A, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: Correlation with clinical disease stages. Hepatology 2002; 35:190198.
  • 38
    Dries V, von Both I, Muller M, Gerken G, Schirmacher P, Odenthal M, et al. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology 1999; 29:223229.
  • 39
    Kagi D, Hengartner H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol 1996; 8:472477.
  • 40
    Nelson DR, Marousis CG, Davis GL, Rice CM, Houghton M, Lau JYN. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158:14731481.
  • 41
    Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, Chisari FV. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997; 100:23762385.
  • 42
    Guidotti L, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:2531.
  • 43
    Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35:694703.
  • 44
    Doherty PC. The numbers game for virus-specific CD8+ T cells. Science 1998; 280:227232.
  • 45
    Gruner NH, Gerlach TJ, Jung M-C, Diepolder HM, Schirren CA, Schraut WW, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181:15281536.
  • 46
    Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 9:14991512.
  • 47
    Lauer G, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, et al. Comprehensive analysis of CD8+ T cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76:61036113.
  • 48
    Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, et al. Broad specificity of virus-specific CD4+ T-helper-cell in resolved hepatitis C virus infection. J Virol 2002; 76:1258412595.
  • 49
    Thimme R, Oldach D, Chang K-M, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:13951406.
  • 50
    Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169:34473458.
  • 51
    Gruener HN, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8+ T lympocytes after infection with hepatitis C virus. J Virol 2001; 75:11211130.
  • 52
    Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000; 20:127142.
  • 53
    Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinases and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:34873493.
  • 54
    Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346355.
  • 55
    Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002; 123:10701083.
  • 56
    Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Buschenfelde KHM. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol 1999; 31:407415.
  • 57
    National Institutes of Health. Viral resistance to antiviral therapy of chronic hepatitis C. Available at: Accessed September 4, 2003.